Talabostat - BioXcel Therapeutics

Drug Profile

Talabostat - BioXcel Therapeutics

Alternative Names: BXCL 701; Talabostat mesilate; Talabostat mesylate

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inveni
  • Developer BioXcel Therapeutics
  • Class Antineoplastics; Boronic acids; Dipeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 8 inhibitors; Dipeptidyl peptidase 9 inhibitors; Fibroblast activation protein antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 13 Nov 2017 BioXcel Therapeutics and Nektar Therapeutics agree to co-develop talabostat in combination with NKTR 214 (Combination therapy) in USA for Cancer
  • 03 Nov 2017 Phase-I clinical trials in Solid tumours in USA (PO) prior to 03/11/2017 (BioXcel pipeline November 2017)
  • 16 May 2017 BioXcel Therapeutics plans a phase Ib/II trial for Solid tumours (Combination therapy) in Q2 2017 (BioXcel website, Inveni website, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top